Fluoxetine dose and outcome in antidepressant drug trials

European Journal of Clinical Pharmacology

Volumn 58, Issue 6, 2002, Pages 379-386

  Barbui, Corrado ^a   Hotopf, Matthew ^b   Garattini, Silvio ^c  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Antidepressants; Clinical trials; Dose; Fluoxetine; Outcome

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; HETEROCYCLIC COMPOUND; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REGISTER; TREATMENT FAILURE;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIAS (EPIDEMIOLOGY); DEPRESSION; FLUOXETINE; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0036378906     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-002-0497-7     Document Type: Article

References (9)

1. Geddes J, Freemantle N, Harrison P, et al (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321:1371-1376
2. Garattini S, Liberati A (2000) The risk of bias from omitted research. Evidence must be independently sought and free of economic interests. BMJ 321:845-846
3. Whooley MA, Simon GE (2000) Managing depression in medical outpatients. New Engl J Med 343:1942-1950
4. Barbui C, Hotopf M, Freemantle N, et al (2000) Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. In: Cochrane Collaboration. Cochrane Library. Issue 4. Oxford: Update Software
5. Barbui C, Hotopf M (2001) Amitriptyline versus the rest: still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry 178:129-144
6. Kent JM (2000) SnaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 355:911-918
7. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
8. StataCorp (1995) Stata statistical software: release 4. Stata Corporation, College Station, TX
9. Horton R (2000) The less acceptable face of bias. Lancet 356:959-960